Clinical trials: Acute Ischemia
Acute Ischemic Stroke
A Study to Evaluate the Safety and Efficacy of Multiple Doses of LT3001 Drug Product in AIS Subjects
This is a phase II, double-blind, randomized, placebo-controlled study to evaluate the safety and efficacy of multiple doses of LT3001 drug product in subjects with acute ischemic stroke (AIS)
- Trial name
- BRIGHT (NCT05403866)
- Testing
- LT3001 Drug Product
- Where
- United States
- Volunteers
- 89 people
- Sponsor
- Lumosa Therapeutics Co., Ltd.
Myocardial Infarction
A Trial on Efficacy and Safety of Full Dose Tenecteplase Combined With Unfractionated Heparin (UFH) or Enoxaparin in Acute Myocardial Infarction (AMI) in the Prehospital Setting
The primary objective of ASSENT 3 Plus (the same as for ASSENT 3) was to evaluate the safety and efficacy of full dose tenecteplase combined with unfractionated heparin (UFH, group A) and full dose tenecteplase combined with…
- Trial name
- ASSENT 3 Plus (NCT02181998)
- Testing
- Full dose tenecteplase, Unfractioned heparin, Enoxaparin
- Volunteers
- 1,606 people
- Sponsor
- Boehringer Ingelheim
Ischemic Stroke, Ischemia
Biomarkers of Acute Stroke in Clinic
The proposed study will investigate the clinical use of the ISCDX test that may differentiate between diverse stroke etiologies as listed below: Aim 1: Differentiate between cardioembolic and large artery atherosclerotic ischemic…
- Conditions
- Ischemic Stroke, Ischemia, Atrial Fibrillation, Transient Ischemic Attack
- Trial name
- BASIC (NCT03897478)
- Testing
- ISCDX blood test
- Where
- United States
- Volunteers
- 500 people
- Sponsor
- Ischemia Care LLC
Unstable Angina, Acute Myocardial Infarction
Prevalence of Sleep Disordered Breathing
A novel technique in identifying unspecified sleep apnea has been developed. This technique uses signals typical acquired from a bedside monitor that is found in critical care environments.
- Conditions
- Unstable Angina, Acute Myocardial Infarction, Congestive Heart Failure
- Trial name
- NCT01011647
- Where
- United States
- Volunteers
- 53 people
- Sponsor
- GE Healthcare
Coronary Artery Disease, Chronic Stable Angina
LEADERS FREE IV (RCT): BioFreedom™ Ultra vs BioFreedom™ in HBR Patients
This study aims to demonstrate that the BioFreedom™ Ultra Drug Coated Stent (DCS) is non-inferior to the BioFreedom™ DCS, with respect to in-stent late lumen loss, and that it has safety characteristics similar to the BioFreedom™…
- Conditions
- Coronary Artery Disease, Chronic Stable Angina, Unstable Angina, Silent Ischemia
- Trial name
- NCT06657326
- Testing
- BioFreedom™ Ultra cobalt-chromium Biolimus A9™-coated stent, BioFreedom™ stainless steel Biolimus A9™-coated stent
- Where
- 6 sites in Malaysia
- Volunteers
- 444 people
- Sponsor
- Biosensors Europe SA
Acute Coronary Syndrome
"Me and My Heart" Study
An electronic device application (APP) "Mein Herz und ich" has been developed specifically for acute coronary syndrome (ACS) patients who are prescribed to Brilique (ticagrelor) to increase adherence to treatment (medication and…
- Trial name
- eMocial (NCT02615704)
- Testing
- Active group with MEMS, Active group without MEMS, Control group with MEMS
- Where
- 31 sites in Germany
- Volunteers
- 677 people
- Sponsor
- AstraZeneca
Acute Peripheral Arterial Occlusion
A Study of Intra-thrombus Plasmin (Human) In Acute Peripheral Arterial Occlusion
The primary purpose of this Phase 2 study is to optimize Plasmin delivery by comparing different delivery regimens in patients with peripheral arterial occlusion.
- Trial name
- NCT01222117
- Testing
- Plasmin, Plasminogen Activator
- Where
- 39 sites in United States, Belgium and 10 more
- Volunteers
- 174 people
- Sponsor
- Grifols Therapeutics LLC
Acute Ischemic Stroke
WOLF - Feasibility Neurothrombectomy Study in Acute Ischemic Stroke Patients
This study is being conducted as a feasibility clinical investigation to collect safety and technical performance data of the WOLF Thrombectomy Device for the removal of thrombus in the neurovasculature.
- Trial name
- WOLF (NCT03781622)
- Testing
- WOLF Thrombectomy Device
- Where
- 2 sites in Canada
- Sponsor
- 880 Medical, LLC
Acute Coronary Syndrome
PK/PD Study of Vicagrel and Clopidogrel in Healthy Subjects With Different CYP2C19 Metabolizers
This clinical study will adopt an open-label, randomized, multiple-dose, two-crossover design to explore the pharmacokinetic and pharmacodynamic profiles of Vicagrel Capsules and Clopidogrel Tablets in Healthy Subjects with…
- Trial name
- NCT05162053
- Testing
- vicagrel Capsules, Clopidogrel Tablets
- Where
- 3 sites in United States, China
- Volunteers
- 128 people, healthy volunteers welcome
- Sponsor
- Jiangsu vcare pharmaceutical technology co., LTD
Acute Coronary Syndrome
Clinical Study to Compare the Pharmacokinetic Characteristics and Safety Between CKD-357 and D578 in Healthy Volunteers
A randomized, open-label, single dose, crossover study to evaluate pharmacokinetic profiles and safety/tolerability of CKD-357 in healthy volunteers
- Trial name
- NCT03671941
- Testing
- D578, CKD-357
- Where
- South Korea
- Volunteers
- 31 people, healthy volunteers welcome
- Sponsor
- Chong Kun Dang Pharmaceutical
Myocardial Infarction, Acute, Myocardial Infarction
A Behavioral Economics-Based Telehealth Intervention to Improve Post-MI Medication Adherence
The proposed study is a pilot randomized clinical trial (RCT). Participants in the intervention arm will participate in a 90-day adherence promotion program based on the theory of behavioral economics and administered through the…
- Trial name
- NCT03022266
- Testing
- Financial Incentive and Mobile Phone App
- Where
- United States
- Volunteers
- 130 people
- Sponsor
- Wellth Inc.
Coronary Artery Disease
Sprinter Legend Balloon Catheter
Open label, single-arm trial to study the safety and effectiveness of the Sprinter Legend 1.25 mm angioplasty balloon.
- Trial name
- NCT00961311
- Testing
- Percutaneous Coronary Intervention, Sprinter Legend 1.25mm Balloon Catheter
- Where
- United States
- Volunteers
- 51 people
- Sponsor
- Medtronic Vascular
Stroke, Cerebral Ischemia
Ancrod (Viprinex™) for the Treatment of Acute, Ischemic Stroke
The primary purpose of this study is to determine whether a brief intravenous infusion of ancrod started within 6 hours of stroke onset improves functional outcome at 3 months.
- Conditions
- Stroke, Cerebral Ischemia, Brain Infarction
- Trial name
- NCT00141011
- Testing
- Ancrod (Viprinex)
- Where
- 100 sites in United States, Australia and 8 more
- Volunteers
- 277 people
- Sponsor
- Neurobiological Technologies
Ischemic Stroke
Study of Efficacy and Safety of MEXIDOL® in Ischemic Stroke Therapy
The purpose of this study is to evaluate the efficacy and safety of long-term sequential therapy with Mexidol® in long-term sequential treatment of patients in the acute and early recovery periods of hemispheric ischemic stroke…
- Trial name
- EPICA (NCT02793687)
- Testing
- Mexidol
- Where
- 11 sites in Russia
- Volunteers
- 150 people
- Sponsor
- Pharmasoft
Acute Myocardial Infarction
Bivalirudin Infusion for Ventricular Infarction Limitation
The purpose of this study is to evaluate whether the use of bivalirudin will reduce extent of the damage done to the heart muscle in participants who suffered a heart attack, compared to the comparator treatment (heparin).
- Trial name
- BIVAL (NCT02565147)
- Testing
- PPCI, Bivalirudin, Heparin
- Where
- 4 sites in France, Netherlands
- Volunteers
- 78 people
- Sponsor
- The Medicines Company
Acute Coronary Syndrome
Ticagrelor Removal Study Using CytoSorb® 300 mL Device During CPB in Patients Undergoing Emergent Cardiothoracic Surgery
The aim of CyTation is to demonstrate intra-operative removal of ticagrelor by CytoSorb® hemadsorption in patients on ticagrelor undergoing emergent cardiothoracic surgery requiring CPB, using platelet reactivity to adenosine…
- Trial name
- CyTation (NCT04625764)
- Testing
- Blood sampling and analysis
- Where
- 4 sites in Germany, Luxembourg
- Volunteers
- 6 people
- Sponsor
- CytoSorbents Europe GmbH
Acute Ischemic Stroke
A Study of XY03-EA Tablets in the Treatment of Acute Ischemic Stroke
Overall Design: a multicenter, randomized, double-blind, placebo-controlled, parallel-group, dose-exploration study. Main outcome: 1.To evaluate the efficacy and safety of XY03-EA tablets in the treatment of acute ischemic stroke.
- Trial name
- XY03-EA (NCT05515393)
- Testing
- XY03-EA
- Where
- China
- Volunteers
- 420 people
- Sponsor
- Shijiazhuang Yiling Pharmaceutical Co. Ltd
Myocardial Infarction
Safety Study of Bone Marrow Derived Cells to Treat Damaged Heart Muscle
Certain types of cells located in bone marrow may help the body recover after an injury. These cells may be able to help the body repair heart muscle that has been damaged from a heart attack.
- Trial name
- NCT00361855
- Testing
- NX-CP105
- Where
- 5 sites in United States
- Volunteers
- 18 people
- Sponsor
- Neuronyx
Myocardial Infarction
Safety of TG100-115 for Heart Attack Treated With Angioplasty
TG100-115 is able to reduce the size of heart attacks in pre-clinical models. The hypothesis of this study is that TG100-115 can be given safely to patients who suffer a heart attack and undergo angioplasty to restore blood flow.
- Trial name
- NCT00103350
- Testing
- TG100-115
- Where
- United States
- Volunteers
- 100 people
- Sponsor
- TargeGen
Cardiogenic Shock, Acute Myocardial Infarction
Clinical Evaluation of NIRSense Tissue Oximetry Sensor Monitoring to Early Detect Cardiogenic Shock
This is a prospective, single-center, observational pilot study of the investigational NIRSense Tissue Oximetry Sensor System (Envello Core), a noninvasive wearable sensor patch that uses near-infrared spectroscopy (NIRS) and…
- Conditions
- Cardiogenic Shock, Acute Myocardial Infarction, Acute Decompensated Heart Failure
- Trial name
- NCT07825363
- Testing
- NIRSense Tissue Oximetry Sensor System
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- NIRSense Inc.